Moleculin Biotech, Inc. (Nasdaq: MBRX) announced on November 18, 2026, that the South Korean Ministry of Intellectual Property has issued a decision to grant a patent covering the Company’s method of reconstituting liposomal Annamycin, also known as naxtarubicin. The patent, titled "Method of Reconstituting Liposomal Annamycin," corresponds to Korean patent application No. 10-2022-7000486.
This grant adds South Korea to a growing list of jurisdictions where Moleculin holds or has pending patent protection for Annamycin. The Company’s international intellectual property estate now covers the drug across three complementary technology areas in more than 20 jurisdictions, including North America, Europe, and the Asia-Pacific region.
The three technology areas protected by the portfolio include:
- Formulation: Preparation of Preliposomal Annamycin Lyophilizate, with granted or allowed patents in the U.S., Australia, Canada, China, Europe, India, Israel, Japan, Mexico, Singapore, and Taiwan.
- Reconstitution: The newly granted Korean patent joins existing protection in the U.S., Australia, Canada, China, Europe, Israel, Japan, Mexico, Singapore, Taiwan, and Hong Kong.
- Lung-Targeted Therapies: Intellectual property directed to lung-targeted anticancer therapies using liposomal Annamycin, supporting development in soft tissue sarcoma lung metastases.
The Company is currently conducting the MIRACLE Trial (MB-108), a pivotal, adaptive design, multi-center, randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating Annamycin in combination with cytarabine (AnnAraC) for relapsed or refractory acute myeloid leukemia (AML).